Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Regulus Therapeutics Inc. (RGLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates"
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates"
03/23/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates"
03/09/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2020 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 225 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates"
08/13/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 8, 2019 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 225 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 3, 2019 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10628 Science Center Drive, Suite 100 San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Eighth Amendment to Loan and Security Agreement, by and between the Company and Oxford Finance LLC",
"Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulu s Therapeutic s Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8 million in a two-tranche private placement of equity. The initial tranche of approximately $16.7 million, priced at the market, is anticipated to close on or about May 7, 2019, subject to the satisfaction of customary closing conditions. Investors in the private placement include the Company's two largest existing institutional shareholders, ...",
"Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022 LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc . , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into an amendment with Oxford Finance LLC. The Amendment to the Term Loan, with a principal balance outstanding of $14.7 million, provides the Company with a new twelve-month period of interest-only payments, commencing May 2019 and a two-year extension of its maturity date to May 2022. Upon the closing of the second tranche of the Company's recently announced private financing, the Company will receive an additional twelve-month period of interest-only paym...",
"Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity May 7, 2019 LA JOLLA, Calif., May 7, 2019 /PRNewswire/ — Regulu s Therapeutic s Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche of its previously announced private placement of equity. The Company received gross proceeds of approximately $16.7 million from the sale of 9,730,534 shares of the Company's common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share. In addition, the Company sold 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of...",
"Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates"
03/18/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 18, 2019 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10614 Science Center Drive San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem...",
"Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates"
11/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Regulus Reports Third Quarter 2018 Financial Results and Recent Updates"
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 6, 2018 Regulus Therapeutics Inc. Delaware 001-35670 26-4738379 10614 Science Center Drive San Diego, CA 92121 Registrant's telephone number, including area code: 202-6300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem...",
"Regulus Reports Second Quarter 2018 Financial Results and Recent Updates"
05/10/2018 8-K Quarterly results
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has ele...",
"Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress"
03/07/2018 8-K Quarterly results
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has ele...",
"Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update"
11/08/2017 8-K/A Quarterly results
Docs: "FORM 8-K AMENDMENT NO. 1",
"Regulus Reports Third Quarter 2017 Financial Results and Recent Events"
11/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Regulus Reports Third Quarter 2017 Financial Results and Recent Events"
08/01/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
03/02/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
05/02/2016 8-K Quarterly results
Docs: "Regulus Reports First Quarter 2016 Financial Results and Recent Highlights"
02/22/2016 8-K Quarterly results
Docs: "Regulus Reports Fourth Quarter and Year-End 2015 Financial Results and Recent Highlights"
11/05/2015 8-K Quarterly results
Docs: "Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights"
08/04/2015 8-K Quarterly results
Docs: "Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights"
05/07/2015 8-K Quarterly results
Docs: "Regulus Reports First Quarter 2015 Financial Results and Recent Highlights"
02/18/2015 8-K Quarterly results
Docs: "Regulus Reports Fourth Quarter and Year-End 2014 Financial Results and Recent Highlights"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy